Navigation Links
Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Date:5/8/2008

WEIFANG, Shandong, China, May 8 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China and glucose and starch products that serve as raw materials for food, beverage and industrial production, today announced that it will conduct a conference call at 9:00 a.m. Eastern Time on Friday, May 16, 2008 to discuss the third quarter results of fiscal year 2008.

Shengtai Pharmaceutical's Chief Financial Officer, Ms. Melody Shi will be participating in the conference call. The Company plans to make an earnings announcement prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 800- 688-0796. International callers should dial 617-614-4070. When prompted by the operator, mention Conference Passcode 502 870 72.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Friday, May 16 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers should dial 617-801-6888, and enter the passcode 924 807 90.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc. please visit http://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Company Contact:

Ms. Melody Shi

CFO

Shengtai Pharmaceutical, Inc.

Tel: +1-949-468-7078

Email: shengtaicfo@hotmail.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY Office)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgelite.com


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
6. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
7. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced a large-scale ... broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization part of ... a needle stick and more importantly, helps our staff members locate a vein that ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD diagnosis every nine minutes, ... , The grants are awarded through a competitive application process and reviewed by APDA’s ... backgrounds and expertise in all areas relevant to PD research. The SAB meets ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... Lake Orion, Rochester, Michigan (PRWEB) , ... August ... ... now offer treatment options to patients suffering from chronic pelvic pain. In ... treatment of various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during ...
(Date:8/16/2017)... ... August 16, 2017 , ... With low back pain afflicting 8 of 10 Americans at ... kissing cousin – upper back pain. But this equally vexing condition stems from a variety ... Kaixuan Liu, MD, PhD , founder and president of Atlantic Spine Center. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/11/2017)... Israel , Aug. 11, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... on Monday, August 14 and host a conference call ... quarter 2017 operating and financial results and its strategy ... will be hosted by Erez Raphael , Chief ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
Breaking Medicine Technology: